ClinicalTrials.gg
Active, not recruitingNCT05899231OPALUpdated Nov 4, 2026

Online Prehabilitation for Patients Awaiting Liver Transplantation

An interventional study of Prehabilitation Programming in Cirrhosis, Liver, Liver Transplant Surgery and Liver Disease, sponsored by University of Alberta. Active, not recruiting at 6 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Alberta · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
179
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 46 studies in Liver Cirrhosis with a site in Canada — 7 open to participants now, 11 under way, 2 of them phase 3. Liver Cirrhosis · Canada.

Enrollment
17th of 35
179 · median 151
Started
2023
with 2 others
No phase
13 of 46
1 open now
Primary completion
2026-08
later than 2 of 10 live
Registered
38th of 46
by date
Lead sponsor
4 of 46
University of Alberta

Among the 46 studies in Liver Cirrhosis with a site in Canada, this one is the 17th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 38th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

7 of the 46 studies in Liver Cirrhosis with a site in Canada are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Liver Cirrhosis with a site in Canada, or all of them as a file.
02

Study summary

Physical frailty is common in patients awaiting liver transplantation and has been associated with poor health outcomes. There is promising data from small studies showing that behavioural, nutrition, exercise therapy (prehabilitation) improves physical function in patients while they are waiting for a liver transplant.

The proposed trial will assess if a 12-week online prehabilitation program improves physical function in patients listed for liver transplantation. Over 4 years, 177 patients will be recruited from 6 transplant centres across Canada and will be randomized to receive either the online prehabilitation program or usual care.

The primary outcome of physical function will be evaluated using the FTSST at baseline and 12 weeks (or last timepoint before transplant) assessed virtually or in-person. Secondary outcomes include liver specific physical frailty, aerobic fitness, health-related quality of life (QoL), participant experience and acceptability. Exploratory outcomes include other virtual and in-person physical function measures, covert hepatic encephalopathy (CHE), sarcopenia, malnutrition, adherence, behaviour factors, clinical and post-transplant outcomes. Results will be compared between the intervention and usual care groups.

Read the detailed description

This multi-centre randomized controlled trial (RCT) will be completed across the six major LT programs in Canada: Vancouver, Edmonton, Calgary, Toronto, London, and Montreal.

Participants involved in this study will be LT transplant candidates with cirrhosis who are receiving care at one of the six participating LT programs.

Participants will be assessed for eligibility, provided informed signed consent, complete baseline testing and then be randomized to the prehabilitation arm or usual care. Participants will be randomized in a 2:1 ratio between groups.

Prehabilitation Arm:

The 12 week prehabilitation program includes exercise, nutrition and psychological components that is accessed through the online digital web platform.

  • The nutrition program includes a nutritional assessment, provision of a daily protein intake target (1.2-1.5 g/kg/day), online group sessions, and follow ups. Participants will also be provided with a clinically tested whey protein powder supplement with dosage based on their malnutrition scoring done at baseline. Follow ups will also be provided based on malnutrition scoring done at baseline.
  • The exercise program includes an exercise assessment, follow along exercise videos, and weekly virtual live exercise sessions. The exercise specialist will advise one of three levels of exercise programming for each participant. Participants will be advised to complete 3 exercise sessions weekly from a combination of virtual group sessions and follow along videos and to participate in planned aerobic activity as much as possible.
  • The weekly acceptance and commitment therapy based educational videos focus on reducing stress and anxiety and improving motivation and adherence.

Control/Usual Care Arm:

This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform. A short questionnaire will be sent to control participants every 4 weeks to track changes in physical activity.

Post-Transplant follow-up In the subgroup of patients who undergo LT, the same in-person and virtual testing will be carried out at 12 weeks post-transplant (timing may vary due to site clinic flow)

Data Collection Plan

Sample size calculations are based on the primary outcome (the chair stand test: time to complete 5 sit-to-stands) using individual data from our local exercise study in cirrhosis (n=59), plus our sit-to-stand data from our study of 694 patients. After accounting for lack of trial completion, loss to follow up, the total sample size is 177, with 59 participants in the control and 118 in the intervention arm.

  1. Quantitative outcomes: Baseline and primary/secondary/exploratory outcome data will be collected with in-person and/or virtual visits at baseline, week 12 (end of trial) and 12 weeks post-transplant (in the subgroup of patients who undergo LT). Charts will be reviewed for information on death, hospitalization, ambulatory care visits, medications and transplantation for up to 2 years after randomization in all participants. Dietary intake data (24-hour recall) may be collected using third party software.
  2. Qualitative data: Interviews/Focus groups will be conducted at the end of the study in a virtual format. Participation in the interviews/focus groups will be optional.

Types of analyses

  1. Quantitative outcomes: Baseline demographic and clinical characteristics will be compared between groups to identify differences that may exist despite randomization. Continuous variables will be screened for assumptions of normality, and descriptive analyses will be presented for participant demographics, medical and outcome variables. Sex will be used in subgroup analysis of primary and secondary outcomes. It will also be a covariate for exploratory analysis in corresponding models. All analyses will adhere to the intention-to-treat principle.
  2. Qualitative data: Qualitative data will be analyzed inductively following a theoretical thematic approach. Data will be coded, with codes combined into larger categories and theme, with the goal of highlighting participant experiences and acceptability (barriers, facilitators) of the OPAL platform and intervention. Data collection and analysis will occur concurrently in order to enable refinement of interview/focus guide questions and deeper exploration of emerging themes.

Primary outcome: The primary outcome (sit to stand test; time to do 5 sit-to-stands) will be analyzed by linear mixed models with random effects, adjusted for baseline score as a covariate. Sites will be entered as random effects.

Secondary/exploratory outcomes: (1) Quantitative outcomes: Similar types of models will be used for continuous secondary/exploratory outcomes. To examine predictors of exercise and nutrition adherence (e.g. COM-B results), generalized linear models with binary outcome will be employed. To evaluate the potential effect of selected demographic variables on outcomes, as an exploratory analysis, models will be adjusted for clinically significant variables (e.g. sex, gender, digital technology proficiency). Results will be primarily descriptive. Exploratory per-protocol analysis will be performed, and the results will be presented if substantial differences are found between this group and the intention-to-treat group.

03

Conditions studied

  • Cirrhosis, Liver
  • Liver Transplant Surgery
  • Liver Disease

Keywords

  • frailty
  • transplant
  • nutrition
  • exercise
  • ehealth
  • application
  • wellness
  • prehabilitation
  • sarcopenia
  • malnutrition
  • physical function
  • digital
  • virtual
  • online
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

≥18 years old with cirrhosis (confirmed with transient elastography by FibroScan, histology, or imaging-based assessment with compatible clinical picture), referred for transplant and are assessed to have a high likelihood of being listed according to a preliminary review by hepatologist or are already listed for LT, are pre-frail or frail on the liver frailty index (LFI) or (added August 30, 2024) pre-frail or frail on the TeLeFI (prefrail LFI 3.2-4.3 and frail LFI ≥4.4), have English or French language proficiency, and own an internet-connected device.

Exclusion criteria

Exclusion Criteria:

  • Listed for living related donor transplantation with expected time on the wait list \<12 weeks, or model for end-stage liver disease (MELD-Na) Score >26 (Justification: time to transplant is very short)
  • Robust status on frailty testing (LFI 0-3.1) (Justification: unlikely to see benefit)
  • Unable to provide
  • Presence of a clinical condition that makes the intervention unsafe or infeasible (e.g. unable to follow instruction) or unsafe environment for virtual participation
  • less than 6 months, compassionate care (clinician judgment) (Justification: unlikely to see benefit)
  • Recent variceal bleed or history of varices not on adequate prophylaxis (Justification: acute exercise increases portal pressure
  • Transplant indication is cholangiocarcinoma.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
179 participants (actual)

Study arms

  • Experimental
    Prehabilitation Group

    The prehabilitation group will be provided with access to the online digital web platform which contains the weekly acceptance and commitment therapy based education videos, nutrition intervention, and exercise intervention.

    Behavioral: Prehabilitation Programming

  • No intervention
    Usual Care

    This group will receive standard care for LT candidates with cirrhosis and will be provided with standard online exercise, nutrition, and behavioural resources. Control participants will not receive access to the online digital platform.

Interventions

  • BehavioralPrehabilitation Programming

    12-weeks of online prehabilitation programming including: 1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk. 2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos). 3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence.

06

What researchers measure

Primary outcomes

  1. Change in time to do 5-sit-to-stands from baseline

    A time to complete 5 chair stands of \>15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform

    Time frame: Week 0

  2. Change in time to do 5-sit-to-stands from baseline

    A time to complete 5 chair stands of \>15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform

    Time frame: Week 12

Secondary outcomes

  1. Change in liver frailty index from baseline

    Liver frailty will be assessed with a cirrhosis-specific tool. The in-person LFI which includes grip strength, chair stand and balance testing, or the virtual TeLeFI which includes virtual FTSST, three stance balance test, and selected questions from validated surveys. The LFI is an independent predictor of waitlist mortality and hospitalization. The LFI score can be calculated using an online calculator (available at http://liverfrailtyindex.ucsf.edu), with patient physical frailty categorized as robust, prefrail, and frail according to their index (index \< 3.2, robust; 3.2-4.5, prefrail; and \>4.5, frail). Higher scores mean a worse outcome.

    Time frame: Week 0

  2. Change in liver frailty index from baseline

    Liver frailty will be assessed with a cirrhosis-specific tool. The in-person LFI which includes grip strength, chair stand and balance testing, or the virtual TeLeFI which includes virtual FTSST, three stance balance test, and selected questions from validated surveys. The LFI is an independent predictor of waitlist mortality and hospitalization. The LFI score can be calculated using an online calculator (available at http://liverfrailtyindex.ucsf.edu), with patient physical frailty categorized as robust, prefrail, and frail according to their index (index \< 3.2, robust; 3.2-4.5, prefrail; and \>4.5, frail). Higher scores mean a worse outcome.

    Time frame: Week 12

  3. Changes in virtual physical function testing over time (2-min step test)

    The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing

    Time frame: Week 0

  4. Changes in virtual physical function testing over time (2-min step test)

    The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing

    Time frame: Week 12

  5. Change in health-related quality of life from baseline (CLDQ)

    The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

    Time frame: Week 0

  6. Change in health-related quality of life from baseline (CLDQ)

    The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

    Time frame: Week 12

  7. Change in health-related quality of life from baseline (EQ5D5L and EQVAS)

    The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

    Time frame: Week 0

  8. Change in health-related quality of life from baseline (EQ5D5L and EQVAS)

    The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

    Time frame: Week 12

  9. Qualitative Acceptability Data

    Inductive analysis of post-trial semi-structured interviews/focus groups with participants

    Time frame: Week 12

Other outcomes

  1. Change in time to do 5-sit-to-stands from baseline

    A time to complete 5 chair stands of \>15 seconds predicts morbidity and mortality in patients with cirrhosis. This test shows promise as a frailty measure that could be evaluated over a virtual platform Completed at week 8 to account for the possibility of transplantation or loss-to-follow-up before the end of the 12 weeks.

    Time frame: Week 8

  2. Change in sarcopenia from baseline

    Calf circumference is a simple measure for appendicular skeletal muscle and predicting sarcopenia

    Time frame: Week 0

  3. Change in sarcopenia from baseline

    Calf circumference is a simple measure for appendicular skeletal muscle and predicting sarcopenia

    Time frame: Week 12

  4. Change in distance in the 6 minute walk test from baseline

    6MWT distance correlates with waitlist mortality and QoL and is recommended by the American Society of Transplantation. It is associated with protein intake, activity level and physical function/ frailty.

    Time frame: Week 0

  5. Change in distance in the 6 minute walk test from baseline

    6MWT distance correlates with waitlist mortality and QoL and is recommended by the American Society of Transplantation. It is associated with protein intake, activity level and physical function/ frailty.

    Time frame: Week 12

  6. Change in covert hepatic encephalopathy from baseline

    The EncephalApp Stroop (Stroop) test is a reliable, easy-to-use diagnostic test for CHE. It evaluates psychomotor speed and cognitive flexibility.

    Time frame: Week 0

  7. Change in covert hepatic encephalopathy from baseline

    The EncephalApp Stroop (Stroop) test is a reliable, easy-to-use diagnostic test for CHE. It evaluates psychomotor speed and cognitive flexibility.

    Time frame: Week 12

  8. Change in health-related quality of life from baseline (EQ5D5L and EQVAS)

    The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

    Time frame: Week 8

  9. Change in health-related quality of life from baseline (CLDQ)

    The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

    Time frame: Week 8

  10. Change in 6-item COM-B scale over time during intervention

    Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 \[strongly disagree\] to 7 \[strongly agree\]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation

    Time frame: Week 4

  11. Change in 6-item COM-B scale over time during intervention

    Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 \[strongly disagree\] to 7 \[strongly agree\]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation

    Time frame: Week 8

  12. Change in 6-item COM-B scale over time during intervention

    Perceived capability, opportunity, and motivation will be assessed over the trial period to understand how the COM-B impacts adherence. Each item is scaled (0 \[strongly disagree\] to 7 \[strongly agree\]) and 3 subscores are computed. A higher score means higher perceived capability, opportunity, and motivation.

    Time frame: Week 12

  13. Change in health-related quality of life from baseline (EQ5D5L and EQVAS)

    The EuroQoL 5-D-5L and visual analog scale (EQ-VAS) are generic tools also validated in LT candidates and recipients. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

    Time frame: Post-transplant (12 weeks after transplant date)

  14. Change in health-related quality of life from baseline (CLDQ)

    The disease-specific Chronic Liver Disease Questionnaire (CLDQ) is validated in cirrhosis. Overall CLDQ scores calculated for each domain range from 1 (most impaired) to 7, with higher scores indicating a minimum frequency of symptoms and hence a better HRQOL.

    Time frame: Post-transplant (12 weeks after transplant date)

  15. Changes in virtual physical function testing over time (Single leg balance test)

    The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing

    Time frame: Week 0

  16. Changes in virtual physical function testing over time (Single leg balance test)

    The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing

    Time frame: Week 8

  17. Changes in virtual physical function testing over time (Single leg balance test)

    The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing

    Time frame: Week 12

  18. Changes in virtual physical function testing over time (Single leg balance test)

    The single leg balance test is used to assess static postural and balance control. The test assesses the length of time the subject can maintain their balance The literature supports good correlation of this virtual measure when compared to in-person testing

    Time frame: Post-transplant (12 weeks after transplant date)

  19. Changes in virtual physical function testing over time (2-min step test)

    The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing

    Time frame: Week 8

  20. Changes in virtual physical function testing over time (2-min step test)

    The 2-min step test is used to assess aerobic endurance and functional fitness. The subject marches in place for two minutes. The literature supports good correlation of this virtual measure when compared to in-person testing

    Time frame: Post-transplant (12 weeks after transplant date)

  21. Number of participants who died during the 12 week trial

    Death will be collected through chart review

    Time frame: Week 12

  22. Number of hospitalizations and ambulatory clinic visits during the 12 week trial

    Hospitalizations and ambulatory clinic visits will be collected through chart review

    Time frame: Week 12

  23. Number of participants who were transplanted during the 12 week trial

    Data on transplantations occurring during the trial will be collected through chart review

    Time frame: Week 12

  24. Number of participants who died during the 2 years post-study completion

    Death will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.

    Time frame: 2 years post-study completion

  25. Number of hospitalizations and ambulatory clinic visits during the 2 years post-study completion

    Hospitalizations and ambulatory clinic visits will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.

    Time frame: 2 years post-study completion

  26. Number of participants who were transplanted during the 2 years post-study completion

    Data on transplantations occurring during the trial will be collected through chart review. Consent will be obtained to extend this to 2 years of extended follow-up for all participants and to link to administrative data-repositories for follow-on research.

    Time frame: 2 years post-study completion

  27. Economic Evaluation

    Healthcare access and hospital usage will be collected through patient survey.

    Time frame: Week 12

  28. Total Length of stay at time of transplant

    In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain total length of stay at time of transplant

    Time frame: Post-transplant up to 3 months of the trial data collection period

  29. Intensive care unit length of stay at time of post transplant

    In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain intensive care unit length of stay

    Time frame: Post-transplant up to 3 months of the trial data collection period

  30. Days of mechanical ventilation at time of post transplant

    In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain days of mechanical ventilation

    Time frame: Post-transplant up to 3 months of the trial data collection period

  31. Discharge location from hospital at time of transplant

    In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain discharge home from hospital (versus rehabilitation, nursing home or other institutional location)

    Time frame: Post-transplant up to 3 months of the trial data collection period

  32. Readmissions within 30 days at time of transplant

    In participants transplanted within 3 months of the end of the trial data collection period, we will ascertain any readmissions within 30 days.

    Time frame: Post-transplant up to 3 months of the trial data collection period

  33. Malnutrition

    The Patient-Generated Subjective Global Assessment (PG-SGA) is an instrument for assessment of nutrition status in patients with cancer and other diseases. It contains both a patient and a practitioner section. A higher score means worse outcomes. The numerical PG-SGA score provides professionals with clearer guidelines as to the level of medical nutrition therapy needed in a given case, while the A, B, or C rating provides an overall picture of a patient's current status. (A = well nourished, B = moderately malnourished or suspected malnutrition and C = severely malnourished).

    Time frame: Week 0

  34. Malnutrition

    The Patient-Generated Subjective Global Assessment (PG-SGA) is an instrument for assessment of nutrition status in patients with cancer and other diseases. It contains both a patient and a practitioner section. A higher score means worse outcomes. The numerical PG-SGA score provides professionals with clearer guidelines as to the level of medical nutrition therapy needed in a given case, while the A, B, or C rating provides an overall picture of a patient's current status. (A = well nourished, B = moderately malnourished or suspected malnutrition and C = severely malnourished).

    Time frame: Week 12

  35. Adverse events

    Major: death or hospitalization for an event occurring during or up to 3 h after exercise; cardiovascular events (stroke, myocardial infarction); permanent disability; angina, syncope, arrhythmia; variceal bleeding. Minor: hypoglycemia, hyper- or hypotension requiring medical attention, musculoskeletal injury or fall.

    Time frame: Week 12

  36. Changes in health care provider support from baseline

    Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

    Time frame: Week 0

  37. Changes in physical activity levels from baseline

    Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

    Time frame: Week 0

  38. Changes in health care provider support from baseline

    Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

    Time frame: Week 4

  39. Changes in physical activity levels from baseline

    Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

    Time frame: Week 4

  40. Changes in health care provider support from baseline

    Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

    Time frame: Week 8

  41. Changes in physical activity levels from baseline

    Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

    Time frame: Week 8

  42. Changes in health care provider support from baseline

    Chart review will record days of enteral or parenteral nutrition provided during hospitalization or as an outpatient and will also record exposure to the number of non-intervention digital platform based exercise sessions attended through to end of extended follow-up.

    Time frame: Week 12

  43. Changes in physical activity levels from baseline

    Participants will be asked to journal about the amount of exercise they take part in over the course of the 12 week trial and for as long as possible into the extended follow-up period as they are willing to.

    Time frame: Week 12

  44. Changes in functional status from baseline

    The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI

    Time frame: Week 0

  45. Changes in functional status from baseline

    The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI

    Time frame: Week 8

  46. Changes in functional status from baseline

    The TeLeFI assesses frailty and functional status virtually via phone and/or video capability without specialized equipment to identify patients who may be at risk of frailty as defined by the in-person LFI

    Time frame: Week 12

  47. Adherence to prehabilitation program goals

    (i) 70% adherence to target protein intake and protein powder supplementation (assessed by dietary intake, nutrition check ins, platform metrics and monthly nutrition questionnaires), (ii) 70% adherence to exercise sessions (assessed by attendance, check ins, platform metrics) excluding study weeks with interruptions to programming due to health related issues (e.g. transplant dry runs, hospital admissions as these are common in patients awaiting LT)

    Time frame: Week 12

07

Study locations

6 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Aug 2026, 37 months.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's 37 months is close to that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Sep 2026 → Aug 2026 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2023
First posted
Jun 12, 2023
StartActual
Jul 12, 2023
Primary completionActual
Aug 28, 2026was Sep 2026
CompletionEst.
Sep 2027was Sep 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 4, 2026
Primary completion
Sep 2026→Aug 28, 2026 (actual)
Nov 4, 2026
Study completion
Sep 2026→Sep 2027
Nov 4, 2026
Enrollment
177 (estimated)→179 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 2026→Aug 28, 2026 (now actual)
    Study completion Sep 2026→Sep 2027
    Enrollment 177 (estimated)→179 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05899231
Responsible party
Sponsor
First posted
Jun 12, 2023
Start date
Jul 12, 2023
Primary completion
Aug 28, 2026
Completion
Sep 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Puneeta Tandon
principal investigator · University of Alberta

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion